• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Immunotherapy for hepatocellular carcinoma: A promising therapeutic option for advanced disease

    2022-11-29 07:58:40GianlucaCasseseHoSeongHanBoramLeeHaeWonLeeJaiYoungChoFabrizioPanaroRobertoIvanTroisi
    World Journal of Hepatology 2022年10期
    關(guān)鍵詞:分力總則合力

    Gianluca Cassese, Ho-Seong Han, Boram Lee, Hae Won Lee, Jai Young Cho, Fabrizio Panaro, Roberto IvanTroisi

    Abstract

    Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide, and its incidence continues to increase. Despite improvements in both medical and surgical therapies, HCC remains associated with poor outcomes due to its high rates of recurrence and mortality. Approximately 50% of patients require systemic therapies that traditionally consist of tyrosine kinase inhibitors. Recently, however, immune checkpoint inhibitors have revolutionized HCC management, providing new therapeutic options. Despite these major advances, the different factors involved in poor clinical responses and molecular pathways leading to resistance following use of these therapies remain unclear. Alternative strategies, such as adoptive T cell transfer, vaccination, and virotherapy, are currently under evaluation. Combinations of immunotherapies with other systemic or local treatments are also being investigated and may be the most promising opportunities for HCC treatment. The aim of this review is to provide updated information on currently available immunotherapies for HCC as well as future perspectives.

    Key Words: Hepatocellular Carcinoma; Immunotherapy; Hepatocellular Carcinoma management; Hepatocellular Carcinoma therapy; Molecular targeted therapy

    INTRODUCTION

    Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide, with an estimated global incidence rate of 9.3 per 100000 persons per year and a corresponding mortality rate of 8.5[1]. While the majority of cases are in Eastern Asia, HCC incidence is widely increasing in northwestern Europe as well as in North America. HCC is also the fastest growing cause of cancer-related deaths in US males, tripling in both incidence and mortality rates[2]. The primary risk factors for HCC include underlying cirrhosis (independent of etiology) and chronic infection with hepatitis B virus or hepatitis C virus[3]. Since diabetes, obesity, and metabolic syndrome are also hypothesized to be risk factors associated with the development of metabolic cirrhosis, HCC is expected to become progressively more concerning as a health problem in the near future[4].

    HCC is associated with a poor prognosis. A 5-year overall survival (OS) of 50–70% is only attained if the tumor is still resectable, owing to advances in both surgical and medical therapy[5]. Surgical treatments include liver transplantation (LT) and liver resection, with recurrence rates as high as 20% after LT and 70% after liver resection[6]. LT is the most effective curative treatment for cirrhotic patients, but it is reserved for patients who are ineligible for liver resection or radiofrequency ablation (RFA), as well as transplantable patients with recurrent HCC. Due to organ shortages, long waiting time for donors, and the risk of tumor progression, which leads to patient dropout, this is done[7].

    Accordingly, liver resection is considered the first-line treatment for HCC in patients with compensated cirrhosis[8]. Thermal ablation is considered to be effective only for lesions smaller than 3 cm and when technically feasible[9]. Unfortunately, less than 30% of patients with HCC are eligible for these procedures because most patients have advanced disease or impaired liver function at the time of diagnosis, thus limiting aggressive treatment[10].

    Trans-arterial chemoembolization (TACE) is the treatment of choice for patients with a suitable performance status[11]. Medical therapy is the only viable option for cases with disseminated disease or when other therapies are not feasible. However, HCC is notoriously resistant to chemotherapy and other systemic treatment modalities[12]. To date, systemic therapy is mainly based on the use of sorafenib, a multitargeted kinase inhibitor that improves survival by only 2.3-2.8 mo[13]. Indeed, the global median survival for patients with unresectable HCC is less than 1 year, highlighting the need for novel therapies to treat this disease.

    Owing to an improved understanding of the molecular pathways of HCC carcinogenesis, other molecularly targeted approaches are under investigation. However, the intrinsic drug-metabolizing properties of the liver and other factors likely contribute to the limited efficacy of chemotherapeutics in the treatment of HCC[14]. In this review, we summarize novel immunotherapeutic approaches in HCC, reporting the latest evidence, analyzing their main limitations, and summarizing future perspectives that might overcome these drawbacks.

    PHYSIO-PATHOLOGICAL BASIS

    Liver immune system

    Due to its physiological function, the liver has a peculiar and complex anti-inflammatory immune environment that develops tolerance to harmless foreign molecules, such as food antigens[15]. Kupffer cells (KCs), hepatic stellate cells (HSCs), and liver sinusoidal endothelial cells (LSECs) are the main mediators of this tolerogenic process[16]. KCs produce inhibitory cytokines interleukin 10 (IL-10) and prostaglandins and promote the activation of regulatory T cells (Treg)[17]. HSCs produces hepatocyte growth factor (HGF), that induces the accumulation of Treg cells inside the liver and promotes T-cell apoptosis through programmed death ligand 1 (PDL1) expression[18,19]. LSECs also play a fundamental role in the immune microenvironment of the liver by expressing high levels of PDL1 and actively participating in the induction of Treg cells, mainly through transforming growth factor-β (TGF-β)[20]. KCs, HSCs, and LSECs are antigen-presenting cells (APC)[19,21]. Hepatic dendritic cells (DCs) also contribute to the tolerogenic microenvironment of the liver as they are poor stimulators of effector CD4+ T cells. They express low levels of major histocompatibility complex (MHC) II and co-stimulatory molecules, producing anti-inflammatory prostaglandin E2, which can increase IL-10 secretion and induce Treg cells[22].

    The complex physiological immune-tolerating microenvironments of the liver are altered during the formation and progression of HCC. A progressively and persistently downregulated immune gene profile has been identified to occur during HCC progression, which leads to lower tumor immunity in advanced stages of the disease, together with a physical barrier made of collagen and other matrix proteins that protect tumoral cells[23]. Therefore, an interesting strategy could be to use therapeutic compounds to disrupt collagen and promote intratumoral infiltration by CD8+ lymphocytes trapped in the peritumoral zone[24]. Different approaches to modulating this complex immune microsystem are desirable in combination with immunotherapies for HCC.

    The tumor microenvironment of hepatocellular carcinoma

    The tumor microenvironment (TME) of HCC is the result of complex interactions among hepatic nonparenchymal resident cells, tumor cells, immune cells, and tumor-associated fibroblasts[25]. The TME has important effects on the presence and activity of all signaling molecules, such as cytokines and chemokines, as well as other paracrine factors[26]. This complex cellular interplay has a substantial influence on tumor immune evasion, affecting both innate and adaptive immune responses and often leading to high levels of dysfunctional tumor-infiltrating lymphocytes (TILs) and natural killer (NK) cells[27,28].

    The peritumoral environment at the forefront of HCC development is also important. KCs at this stage show higher levels of PDL1, and hyperactivation of HSCs in this TME is associated with a poor prognosis[29,30]. Similarly, PDL1 expression is higher in CD8+ T cells, which is associated with a higher risk of cancer recurrence, metastasis, and death[31]. Other molecules involved in the immune checkpoint have been identified in HCC and have been shown to correlate with poor prognosis, such as T-cell immunoglobulin, mucin-domain-containing molecule-3 (Tim-3), and lymphocyte-activation gene 3 in TILs and tumor-associated macrophages (TAM)[32].

    Mechanisms of immune evasion in hepatocellular carcinoma

    Several molecular mechanisms of immune evasion have been described in HCC, derived from the alteration of different signaling pathways, although much remains to be explored.

    TGF-β is abundant in the HCC TME and can be produced by tumor cells, TAMs, and Treg cells[25,33]. TGF-β can reduce or eliminate antitumor responses by blocking T-cells and NK cells, inhibiting APC cells and TAMs, and activating Tregs[34-36]. High TGF-β expression has been shown to be associated with poor prognosis in HCC patients, and circulating levels are associated with clinical response to sorafenib and pembrolizumab[37,38].

    Pro-inflammatory cytokines such as tumor necrosis factor and IL-1 are significantly downregulated in the HCC TME and are associated with increased levels of immunosuppressive cytokines, resulting in immune response dysfunction (IL-4, IL-5, IL-8, and IL-10)[23]. This has been associated with poor prognosis and worse clinical outcomes in several cancer types, including HCC[39]. Another pro-inflammatory cytokine, type I interferon (IFN), can activate the immune response; however, it can also trigger anti-inflammatory signals through the production of IL-10[40]. IL-10 is upregulated in HCC and is produced by TAMs and Treg cells. It can impair the capacity of APCs to recruit T cells and promote the upregulation of PDL1 in monocytes[41]. Furthermore, IL-10 Levels are associated with the number of myeloid-derived suppressor cells (MDSC)[42]. Representing the complexity of the TME, low IFNγ levels are associated with a worse prognosis in HCC[43].

    Chemokines also play a fundamental role in recruiting Tregs via chemokine receptor 6 (CCR6) and chemokine ligand 20 (CCL20)[44]. The level of both Treg cells and TAMs in the liver is associated with poor prognosis in HCC[45,46]. A rare recently discovered immunosuppressive cell is represented by the T helper 17 cells, that produce high levels of PD1and inhibit NK cell function. Then there are the hepatic neutrophils that can recruit macrophages and Treg cells[47,48].

    Vascular endothelial growth factor (VEGF) is a soluble molecule produced by tumor cells and the surrounding stroma[49]. It is known to promote tumor angiogenesis, but it can also act as an immune modulator by inhibiting liver APCs and activating MDSCs and Treg cells[50]. This immunomodulatory action of VEGF inhibitors may play a role into their anti-tumor activity. The presence of many possible immunoregulatory targets in the HCC TME has stimulated the investigation of different immunotherapies in HCC, some of which have been shown to be effective for other malignancies.

    IMMUNE CHECKPOINT INHIBITORS

    Immune checkpoint inhibitors (ICIs) are monoclonal antibodies directed against extracellular ligands involved in the suppression of antitumor immune responses. These proteins are expressed by both cancer cells and the immune system cells. To date, only two categories of molecular targets have been examined in clinical trials, PD-1 and CTLA-4, and only two checkpoint inhibitors have been approved for use in HCC by the United States Food and Drug Association (FDA)[51,52], while many more promising targets are being investigated.

    Nivolumab

    Nivolumab is a human anti-PD-1 IgG4 monoclonal antibody targeting PD-1, currently used as a secondline therapy for HCC after approval by the FDA in 2017. Checkmate 040, a phase I/II dose escalation and expansion trial, showed substantial tumor reduction and good tolerability in HCC patients. In the Checkmate040 study, patients showed a median OS of 15 mo (95%CI: 9.6-20.2), with an objective response rate (ORR) of 15% (95%CI: 6-28)[53]. The median duration of response to nivolumab among the 48 patients was 17 mo (95%CI, 6-24 mo), with a 2-year survival rate higher than 80%[53]. As an unexpected result, patients with PD-1- and PD-L1 expression showed better survival outcomes, with a median OS of 28.1 mo (95%CI: 18.2-n.a.) vs. 16.6 mo in the group with low PD-L1 expression (95%CI: 14.2-20.2).

    CheckMate 459, a phase III trial, comparied the efficacy of nivolumab vs sorafenib as a first-line treatment in 743 HCC patients[54]. In the Nivolumab cohort, the OS outcomes were not statistically significant (median survival 16.4 vs 14.7 mo, HR 0.85; P = 0.07). However, in this study, patients with PD-L1 expression > 1% in the nivolumab arm had a significantly higher ORR (28.2% vs 12.2%). Furthermore, the rate of grade 3 or 4 adverse events in nivolumab arm was only 22%, compared to 49% after sorafenib[54]. Currently, other clinical trials are investigating the role of nivolumab for HCC, either as monotherapy or in combination with other modalities (Tables 1 and 2).

    Pembrolizumab

    Pembrolizumab is an anti-PD-1 IgG4 antibody approved by the FDA in 2018 as a second-line systemic therapy for HCC after sorafenib. A phase II trial, KEYNOTE-224, showed high efficacy and tolerability of pembrolizumab in HCC patients with a significant gain of survival (HR, 0.78; P = 0.023), although it did not meet the prespecified statistical threshold[55]. The ORR was 17% (95%CI: 11-26), while1% of the patients showed a complete response to the treatment and 16% experienced a partial response. The median OS was 12.9 mo (95%CI: 9.7-15.5), and the median progression-free survival (PFS) was 4.9 mo (95%CI: 3.4-7.2). Sixty-two percent of patients showed a good disease control (95%CI: 52-71), while the 25% of patients experienced grade 3 or 4 adverse events, with 1 death[55]. More evidences are expected from KEYNOTE-240 and KEYNOTE-394, two phase III trials investigating the role of Pembrolizumab, that are still ongoing.

    Similarly, trials evaluating the association between pembrolizumab and other treatments are ongoing. A phase Ib trial showed promising antitumor activity of the combination of pembrolizumab with lenvatinib (a multiple kinase inhibitor against VEGF receptors) as a first-line treatment in patients with unresectable HCC[56]. Furthermore, a phase III trial has investigated the safety and efficacy of pembrolizumab in combination with lenvatinib, while the role of pembrolizumab alone as adjuvant therapy after RFA or radiotherapy is still under evaluation (Tables 1 and 2).

    Atezolizumab

    Atezolizumab is an engineered IgG1 monoclonal antibody targeting PD-L1 and was recently approved by the FDA and European Medicines Agency in combination with bevacizumab as a first-line treatment for unresectable HCC. In the open-label phase III IMbrave150 clinical trial, 501 patients were randomly assigned at a ratio of 2:1 to receive atezolizumab plus bevacizumab or sorafenib[57]. The combination of atezolizumab and bevacizumab showed significantly higher 12-months OS, 67.2% (95%CI: 61.3-73.1) vs 54.6% (95%CI: 45.2-64.0), respectively, with 52% and 40% of patients surviving at 18 months, respectively. Similarly, the median PFS was improved at 6.8 months (95%CI: 5.7-8.3) vs 4.3 months (95%CI: 4.0-5.6), respectively (P < 0.001).

    Further studies investigating the combination of atezolizumab with other treatments are ongoing (Table 2). In particular, the COSMIC-312 phase III study tested atezolizumab plus cabozantinib (an oral tyrosine kinase inhibitor against VEGFR, FLT-3, MET, AXL, KIT, Tie-2, and RET) vs sorafenib as firstline therapy. Two phase III studies are enrolling patients to receive atezolizumab plus bevacizumab in combination with TACE or adjuvant therapy after surgery of RFA. Finally, results from several studies investigating other anti-PD-1 antibodies, such as tislelizumab compared to sorafenib, and anti-PD-L1 antibodies, such as durvalumab or avelumab, are expected (Table 2).

    Table 1 Clinical trial involving immunotherapic agents as adjuvant therapy for hepatocellular carcinoma

    Table 2 Ongoing clinical trial involving immunotherapic agents as first line therapy for hepatocellular carcinoma

    VACCINE THERAPY IN HEPATOCELLULAR CARCINOMA

    The development of vaccines against different types of cancer aims to enhance existing tumor-specific responses. Due to altered T cell activity in the HCC TME, vaccine therapy is usually investigated in combination with ICI or other therapies[58]. Although the first HCC vaccines were shown to be safe and have immunologic effects, their clinical efficacy is still limited, possibly because of immunological tolerance to self-antigens that causes them to not be completely tumor-specific[59,60]. Thus, new strategies are currently under investigation.

    Alpha-fetoprotein peptide

    Alpha-fetoprotein (AFP) is a 70-kDa protein expressed during fetal development and in the adult liver. Serum AFP levels are usually not detectable in the adult. However, AFP levels increase in approx-imately 70% of HCC cases, allowing for its use as a biomarker[61,62]. Butterfield et al[63] constructed a human AFP-expressing replication-deficient adenovirus as a new target for T-cell-based immunotherapy. AFP-based therapies have been evaluated in phase I/II trial with two patients with HCC who had an AFP-expressing tumor and who completed a previous treatment for HCC, and their tolerability and safety were confirmed. Additionally, both patients experienced high levels of AFP-specific CD8+ T cells, further confirming their preexisting immunity[64]. Further studies are required to confirm these results.

    Multidrug resistance-associated protein 3

    Multidrug resistance-associated protein 3 (MRP3) is a carrier-type protein that is highly expressed in several human cancers, including HCC[65]. Interestingly, MRP3 is also associated with resistance to sorafenib toxicity in HCC cells[66]. The safety and the immune response to the vaccine based on an MRP3-derived peptide (MRP3765) were tested in a phase I study involving 12 HLA-A24-positive HCC patients[67]. The vaccine showed a good safety profile, with an immune response in 72.7% of the treated cases and a median OS of 14.0 mo (95%CI: 9.6-18.5). OS was notably better than in patients undergoing hepatic arterial infusion chemotherapy without the MRP3 vaccination (median OS 12.0 12.6 mo)[68].

    Glypican-3

    HCC cells sometimes overexpress proteins relative to the surrounding healthy tissue, as is the case for glypican-3 (GPC3)[69]. Therefore, the GPC3-derived peptide vaccine was tested and reported as safe in 33 patients with advanced HCC in a phase I clinical study, showing good results in terms of GPC3-specific immune response[70]. However, only 1 patient developed a partial response, while 19 patients had stable disease. Interestingly, another phase II study investigating the GPC3-derived vaccine as adjuvant therapy showed significantly lower recurrence rates than with surgery alone after 1 year (52.4% vs 61.9%, P = 0. 387) and 2 years (24% vs 48%, P = 0.047)[71].

    Oncolytic viruses

    Oncolytic viruses are viral units engineered to obtain direct lysis of tumor cells, releasing soluble cancer peptides to induce antitumor neoantigen-specific cytotoxic T lymphocyte responses[72]. A phase II study (NCT00554372) assessed the safety of two doses of JX-594 (Pexa-Vec, by testing both low dose or high dose in 30 patients with HCC. All patients experienced dose-dependent flu-like syndrome with fever, rigor, and vomiting within the first few days[73]. Furthermore, when tested as a second-line treatment, there was no significant survival difference when compared to the standard of care (4.2 vs 4.4 mo, 95%CI: 0.78-1.80; P = 0.428)[74]. Other schemes are currently being tested.

    Dendritic cell vaccines

    DCs can be activated with a specific antigen in vitro and then injected into patients to enhance the immune response. Wang et al[75] obtained encouraging antitumor effects in murine models treated with DCs activated by tumor cell lysate. A good tolerability profile was reported after a phase I study testing autologous DCs on 10 patients with cholangiocarcinoma or HCC, and after a phase II clinical trial with 35 patients using DCs[76]. Interestingly, DC infusion enhanced a stronger tumor-specific immune responses in combination with TACE, than TACE alone, even if without improved survival outcomes[77]. However, further clinical trials are warranted.

    New York esophageal squamous cell carcinoma-1

    New York esophageal squamous cell carcinoma-1 (NY-ESO-1) is a promising target antigen owing to its low expression in healthy tissue[78]. A specific CD8+ T cell response to NY-ESO-1b has been reported in 48% of patients with HCC expressing NY-ESO-1 mRNA and HLA-A2[28]. Furthermore, there was a correlation between such response and patient survival. However, no studies have yet been conducted to investigate the clinical response to NY-ESO-1 vaccines in patients with HCC.

    對(duì)于f2的分析如下,每個(gè)電子都受到垂直于導(dǎo)線(xiàn)的分力f2,而導(dǎo)體棒受到向左的力F總則是這些分力f2的合力。我們可以先假設(shè)該導(dǎo)體棒的長(zhǎng)度為L(zhǎng),其橫截面積為S,在單位體積內(nèi)的電荷數(shù)為n,且做定向運(yùn)動(dòng)的自由電子的電量為e。

    ADOPTIVE CELL THERAPY

    Adoptive cell therapy (ACT) is a passive therapy in which lymphocytes are activated and/or expanded ex vivo, and then re-injected into the patient[79]. The treated cells include lymphokine-activated killer (LAK) cells, cytokine-induced killer (CIK) cells, NK cells, TILs, and redirected peripheral blood T cells. These latter cells are genetically programmed to recognize and attack tumor cells.

    Chimeric antigen receptor T cells

    An individual’s own T cells can be engineered to recognize tumor cell surface proteins and, in turn, cause cancer cell death, as demonstrated by approximately six chimeric antigen receptor T cell (CAR T cell) therapies already approved by the FDA since 2017 (all of them for blood cancers). A similar effect was observed by targeting GPC3-positive HCC cells in vitro and in mice[80,81]. Takayama et al[82] published excellent results from a trial of 150 patients who were randomly assigned to receive adjuvant adoptive immunotherapy or no treatment. After a median follow-up of 4.4 years, adoptive immunotherapy decreased recurrence rates by 18% compared with that in controls, with a shorter time to first recurrence [33% (95%CI: 22-4) vs 48% (95%CI: 37-59) at 3 years; 22% (95%CI: 11-34) vs 38% (95%CI: 22-54) at 5 years; P = 0.008]. The immunotherapy group had a significantly longer recurrence-free survival (P = 0.01) and disease-specific survival (P = 0.04). Several phase I and phase II clinical studies are currently evaluating CAR-GPC3 T-cell therapy alone or in combination with fludarabine, cyclophosphamide, or other treatment options.

    Cytokine-induced killer cells

    CIK cells are a heterogeneous population of effector CD3+CD56+NK cells expanded in vitro from peripheral blood mononuclear cells. They are used as pharmacological tools for cancer immunotherapy because they exhibit MHC-unrestricted, safe, and effective antitumor activity. Firsts attempts to develop ACT for HCC were not able to reach the clinical stage owing to the technological complexity and to the low efficacy. A phase II study of 127 patients and a phase III study of 200 patients, in which CIK cells were tested as adjuvant therapy and compared with no adjuvant therapy, showed improved DFS after CIK immunotherapy, although the increase in OS was not statistically significant[83]. Improved OS was observed only in patients diagnosed with tumors > 5 cm in size (P = 0.0002). Furthermore, the combination of CIK immunotherapy and minimally invasive therapies in HCC patients with no history of previous surgery was reported to be safe and feasible, as well[84,85]. As a first-line therapy, the CIK cell treatment followed by TACE and RFA group were compared with those treated with TACE + RFA. Although no significant difference in disease control rates was found between the two cohorts, survival analysis showed that patients in the CIK+TACE+RFA group had a significantly longer median OS of 56 mo (95%CI: 38.09-73.91) compared to 31 mo of TACE+RFA alone (95%CI:24.53-37.47)[85].

    TILs can also be created from fresh tumor tissue to produce tumor-reactive expanding cells, screened on the basis of the ability to recognize autologous tumor cells, and further expanded to obtain several billion active cells[86]. The safety and feasibility of adjuvant TIL therapy were demonstrated in a phase I trial on HCC patients[87]. Current challenges include the capability of further expand tumor-specific T cells and scaling up the manufacturing process.

    OVERCOMING CURRENT LIMITATIONS TO IMMUNOTHERAPY

    Enhancing locoregional therapies

    Locoregional therapies can be a strong ally in the immunologic war against HCC, owing to several advantages. Their relatively easy accessibility makes HCC an ideal target for local interventions, such as thermal ablations or intra-arterial therapies, and image-guided interventions are a common practice in this setting of patients. Therefore, these approaches can intratumorally deliver immunostimulant agents, allowing not only more potent immunological responses but also potentially decreasing toxicity. Indeed, such agents are often quite toxic when administered systemically, causing sepsis-like cytokine release syndrome and systemic inflammation[88]. Thermal ablation has been shown to activate immune responses and T cell infiltration in HCC[89]. Furthermore, to obtain stronger immune stimulation, different locoregional therapies can be combined sequentially or simultaneously with systemic immunotherapy[90].

    Promising results were obtained from the combination of thermal ablation or TACE plus tremelimumab in patients with advanced HCC, with a reported response rate of 26%, a disease control rate of 89%, an OS of 12.3 mo, and 45% of the stabilizations lasting longer than 6 mo[91]. These encouraging data have prompted new clinical trials combining durvalumab/tremelimumab with TACE or RFA, and these trials are ongoing.

    Combination immunotherapy strategies

    The combination of multiple immunotherapies could be another option to overcome the limitations of single treatments. Although this approach could increase the risk of high-grade adverse events, the initial results are encouraging. A combination of nivolumab (NIVO) and ipilimumab (IPI) was tested as a second-line therapy after sorafenib. Following treatment with this combination, patients showed an ORR twice that of the NIVO mono-treated patients (31% and 14%, respectively). Thirty-seven percent of the patients had grade 3-4 treatment-related adverse events, but only 5% had an event leading to therapy discontinuation[92]. Similar results were reported in another study in which nivolumab was tested with cabozantinib (CABO) and ipilimumab, both as double and triple therapies. The median PFS was 5.5 mo for patients in the NIVO + CABO and 6.8 mo for those in the NIVO + IPI + CABO groups, while the median OS was not reached. However, the triple combination led to grade 3-4 treatmentrelated adverse events in 71% of patients, with 20% discontinuing therapy[23]. Similarly, a phase II trial investigating the safety and efficacy of a combination of durvalumab and tremelimumab is currently recruiting patients.

    Immune checkpoint inhibitors can also be combined with oncolytic viruses; this strategy has been tested in several ongoing randomized trials, but without published results. Another study investigated the combination of activated T cell transfer (ATVAC) with an autologous tumor lysate-pulsed DC vaccine as an adjuvant therapy in HCC patients, showing an improved median PFS of 24.5 mo (95%CI: 7.8-41.2) and OS of 97.7 mo (95%CI: 48.6-146.7), compared to a median PFS of 12.6 mo (95%CI: 6.9-18.3) and OS of 41.0 mo (95%CI: 16.3-65.8) of the other group. No adverse events of grade 3 or more were observed[93]. These encouraging results need to be confirmed in future studies.

    Tailoring HCC immunotherapies

    As previously discussed, several trials have shown encouraging results in certain subgroups of HCC patients, although the overall outcomes have not improved much. Identification of patient subsets that would benefit from ICI therapy should be a mainstay of current cancer research. Indeed, the identification of the best candidates for immunotherapies and combination therapies can play a fundamental role not only in achieving the best results but also in saving a substantial amount of funding and healthcare resources. At the same time, a better understanding of patient characteristics could help to avoid related toxicities.

    Some characteristics of the patients in the KEYNOTE-240 and CheckMate 459 trials have already been reported, identifying Asian patients and those with AFP levels > 200 ng/mL as the patient groups showing the best outcomes[54]. The latter study also showed a better OS among patients with vascular invasion or extrahepatic disease. In the IMbrave150 trial, OS and PFS were worse in patients with a nonviral etiology, high AFP levels, no macro-vascular invasion, and extrahepatic disease[57].

    The genetic features of HCC have been identified using next-generation sequencing (NGS), and several biomarkers have been identified as useful for selecting the best candidates for new targeted therapies. NGS analysis detected ten patients with WNT/β-catenin mutations that did not respond to anti–PD-1 or anti–PD-L1drugs, while 50% of CTNNB1 WT cases showed a response[94]. The WNT/βcatenin mutation was also correlated to lower median PFS (2.0 vs 7.4 mo; 95%CI: 2.9-28.8; P < 0.0001) and OS (9.1 vs 15.2 mo; 95%CI: 0.76-8.7; P = 0.11) than WNT/β-catenin wild type. Further studies are needed to determine the clinical implications of NGS in HCC therapy.

    CONCLUSION

    In conclusion, HCC is a widely studied yet challenging disease. Systemic therapies have shown modest results; however, due to tremendous improvements in basic molecular research on anti-tumor immune responses in the TME, a new class of molecular therapies is emerging and changing the HCC therapeutic landscape. Several clinical trials are ongoing, providing hope for an epochal turning point. In our opinion, the development of synergies between immunotherapies and locoregional or radical therapies is likely to be key in the future of HCC therapy. Similarly, another area where a major shift in HCC management may arise is the role of immunotherapy in adjuvant therapy. In fact, immunotherapy used in an adjuvant setting after surgery showed promising results, affecting recurrence rates, which represents a major challenge following surgical therapy. These results suggest the usefulness of immunotherapy, even in early stages, such as in patients undergoing tumor resection or ablation. Importantly, technological advances and recent evidence have also paved the way for the identification of molecular mechanisms involved in sensitivity and resistance to individual agents or combinations, helping advance the era of personalized medicine. We are convinced that these findings may help in the adoption of and adaptation to different types of therapies for individual patients in the near future. Considering the speed and breadth of discoveries in this field, efforts should be made to embed correlative research studies in every new clinical trial.

    FOOTNOTES

    Author contributions: Han HS, Cassese G, Troisi RI, and Panaro F conceived and designed the study; Cassese G and Lee B wrote the manuscript; Han HS, Cho JY, Lee HW, and Troisi RI participated in the coordination of the work and in the final revision. All authors approved the final manuscript.

    Conflict-of-interest statement: All the authors declare that they have no conflict of interest.

    Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BYNC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is noncommercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

    Country/Territory of origin: South Korea

    ORCID number: Gianluca Cassese 0000-0001-9185-2054; Ho-Seong Han 0000-0001-9659-1260; Fabrizio Panaro 0000-0001-8200-4969.

    S-Editor: Liu JH

    L-Editor: A

    P-Editor: Liu JH

    猜你喜歡
    分力總則合力
    中華人民共和國(guó)外商投資法實(shí)施條例 第一章 總則
    金橋(2021年3期)2021-05-21 08:05:40
    “芪”心合力
    外商投資法(一) 第一章 總則
    金橋(2020年7期)2020-08-13 03:07:04
    當(dāng)兩分力的方向不變時(shí),是否分力越大,合力也越大?
    合力
    人走路時(shí)為什么要擺手?
    奧秘(2019年1期)2019-03-28 17:18:47
    《民法總則》第171條第3款評(píng)釋
    法律方法(2018年3期)2018-10-10 03:21:24
    外圓車(chē)削中的切削力分力夾角與切削參數(shù)關(guān)系分析
    論刑法總則
    合力與分力的關(guān)系探究
    成人欧美大片| 国产在线观看jvid| 亚洲熟妇熟女久久| 一级片免费观看大全| www国产在线视频色| 亚洲av中文字字幕乱码综合| 夜夜看夜夜爽夜夜摸| www日本黄色视频网| 九九热线精品视视频播放| 欧美色视频一区免费| 中文字幕最新亚洲高清| 好看av亚洲va欧美ⅴa在| 女人爽到高潮嗷嗷叫在线视频| 午夜福利高清视频| 亚洲熟妇熟女久久| 久久久国产成人免费| 两个人看的免费小视频| 女同久久另类99精品国产91| 亚洲国产精品sss在线观看| 国产一区二区三区在线臀色熟女| 可以在线观看的亚洲视频| 国产成人av激情在线播放| 国产精品亚洲一级av第二区| 久久99热这里只有精品18| 成人午夜高清在线视频| 夜夜夜夜夜久久久久| 亚洲中文日韩欧美视频| 伊人久久大香线蕉亚洲五| 变态另类丝袜制服| av福利片在线| 欧美国产日韩亚洲一区| 亚洲色图av天堂| 搡老岳熟女国产| 免费看美女性在线毛片视频| 夜夜夜夜夜久久久久| 国产亚洲精品av在线| 久久精品人妻少妇| 91av网站免费观看| xxxwww97欧美| 国产午夜精品论理片| 欧美又色又爽又黄视频| 九九热线精品视视频播放| bbb黄色大片| 窝窝影院91人妻| 一区二区三区高清视频在线| 久久久久久久久久黄片| 叶爱在线成人免费视频播放| 女生性感内裤真人,穿戴方法视频| 性色av乱码一区二区三区2| 亚洲国产欧洲综合997久久,| 亚洲熟妇中文字幕五十中出| 亚洲激情在线av| 午夜福利在线在线| 国产爱豆传媒在线观看 | 欧美三级亚洲精品| 一二三四在线观看免费中文在| 好看av亚洲va欧美ⅴa在| 成人欧美大片| 黑人欧美特级aaaaaa片| 成人精品一区二区免费| 亚洲人成网站在线播放欧美日韩| 久久人人精品亚洲av| www.999成人在线观看| 在线观看美女被高潮喷水网站 | 日本免费a在线| 欧美黑人巨大hd| 国产单亲对白刺激| 窝窝影院91人妻| 91九色精品人成在线观看| 国产伦在线观看视频一区| 一级黄色大片毛片| 成人国产一区最新在线观看| 在线观看一区二区三区| 黄色视频不卡| 日韩av在线大香蕉| 午夜老司机福利片| 高清在线国产一区| 日韩欧美在线乱码| 在线观看免费视频日本深夜| 久久欧美精品欧美久久欧美| 精品乱码久久久久久99久播| 丝袜美腿诱惑在线| 别揉我奶头~嗯~啊~动态视频| 亚洲男人的天堂狠狠| 日本熟妇午夜| 亚洲国产精品sss在线观看| 欧美日韩亚洲综合一区二区三区_| 欧美色视频一区免费| 亚洲人成网站高清观看| 日韩免费av在线播放| 91成年电影在线观看| e午夜精品久久久久久久| 欧美乱色亚洲激情| 色噜噜av男人的天堂激情| 亚洲aⅴ乱码一区二区在线播放 | 麻豆国产97在线/欧美 | 黄色 视频免费看| 日韩三级视频一区二区三区| 99精品久久久久人妻精品| 无人区码免费观看不卡| 国产野战对白在线观看| 午夜福利在线在线| 香蕉av资源在线| 我要搜黄色片| 午夜福利成人在线免费观看| 麻豆成人av在线观看| 在线免费观看的www视频| tocl精华| 人人妻人人看人人澡| 村上凉子中文字幕在线| 一个人观看的视频www高清免费观看 | 午夜精品在线福利| 叶爱在线成人免费视频播放| 十八禁人妻一区二区| 99riav亚洲国产免费| 在线观看午夜福利视频| 91av网站免费观看| 嫁个100分男人电影在线观看| 亚洲人成电影免费在线| www.熟女人妻精品国产| 欧美日韩国产亚洲二区| 老司机靠b影院| 亚洲美女视频黄频| 久久中文字幕一级| 99在线视频只有这里精品首页| 亚洲精品国产一区二区精华液| 一级毛片精品| 成人特级黄色片久久久久久久| 成人三级黄色视频| 欧美性猛交黑人性爽| 国产亚洲av嫩草精品影院| 国产精品久久电影中文字幕| 中文资源天堂在线| 亚洲全国av大片| 亚洲国产欧洲综合997久久,| 国产成人影院久久av| 婷婷丁香在线五月| 精品少妇一区二区三区视频日本电影| 亚洲av美国av| 国产视频内射| av福利片在线观看| 亚洲精品美女久久久久99蜜臀| 精品一区二区三区四区五区乱码| 久久久久国产精品人妻aⅴ院| 亚洲成人国产一区在线观看| 国产麻豆成人av免费视频| 亚洲一区二区三区不卡视频| 国产精品久久久久久精品电影| 欧美色视频一区免费| 91在线观看av| 欧美日本亚洲视频在线播放| 男女视频在线观看网站免费 | 精品国产美女av久久久久小说| 精品欧美国产一区二区三| 中文字幕av在线有码专区| 一级a爱片免费观看的视频| 久久精品成人免费网站| 亚洲av中文字字幕乱码综合| 国产不卡一卡二| 黄片大片在线免费观看| 国产亚洲精品综合一区在线观看 | 怎么达到女性高潮| 看免费av毛片| 无遮挡黄片免费观看| 欧美在线一区亚洲| av福利片在线| 性欧美人与动物交配| 高清在线国产一区| 一本大道久久a久久精品| 黄色成人免费大全| 欧美日本亚洲视频在线播放| 婷婷六月久久综合丁香| 国产午夜精品久久久久久| 啪啪无遮挡十八禁网站| 国产69精品久久久久777片 | 国内精品久久久久久久电影| 黄色丝袜av网址大全| 亚洲成av人片在线播放无| 在线观看免费视频日本深夜| 日韩精品免费视频一区二区三区| 波多野结衣高清作品| 在线观看美女被高潮喷水网站 | 非洲黑人性xxxx精品又粗又长| 欧美大码av| 亚洲中文字幕一区二区三区有码在线看 | 在线十欧美十亚洲十日本专区| 女人高潮潮喷娇喘18禁视频| 最近最新中文字幕大全免费视频| 国产精品 国内视频| 熟女少妇亚洲综合色aaa.| 听说在线观看完整版免费高清| 免费在线观看影片大全网站| 中文字幕人成人乱码亚洲影| 亚洲精品美女久久av网站| 嫁个100分男人电影在线观看| 久久久久精品国产欧美久久久| 成年版毛片免费区| 国产精品香港三级国产av潘金莲| 日本 欧美在线| 日本三级黄在线观看| 国产精品98久久久久久宅男小说| 亚洲专区中文字幕在线| 9191精品国产免费久久| 国产一区二区在线观看日韩 | 日韩欧美在线二视频| 国产精品免费视频内射| 黄色女人牲交| 毛片女人毛片| 中文字幕av在线有码专区| 久久人人精品亚洲av| 叶爱在线成人免费视频播放| 国产v大片淫在线免费观看| 欧美日韩瑟瑟在线播放| 久久精品国产亚洲av香蕉五月| 国产精品 国内视频| 午夜成年电影在线免费观看| 亚洲av片天天在线观看| 亚洲精品在线观看二区| 琪琪午夜伦伦电影理论片6080| 久99久视频精品免费| 国产av麻豆久久久久久久| 一进一出抽搐gif免费好疼| av有码第一页| 亚洲人成伊人成综合网2020| 91在线观看av| 国产成人系列免费观看| cao死你这个sao货| 久久久久性生活片| 欧美性长视频在线观看| 国产不卡一卡二| 精品久久久久久久末码| 制服人妻中文乱码| 三级国产精品欧美在线观看 | 亚洲成av人片免费观看| www日本在线高清视频| 久久精品影院6| www.精华液| 欧美又色又爽又黄视频| 欧美色视频一区免费| 精品福利观看| 99国产综合亚洲精品| 黄色a级毛片大全视频| 色在线成人网| 日本一区二区免费在线视频| 欧美绝顶高潮抽搐喷水| 午夜a级毛片| 日本一区二区免费在线视频| 日本熟妇午夜| 天天躁狠狠躁夜夜躁狠狠躁| 国产高清视频在线观看网站| 黄色 视频免费看| 亚洲av美国av| 国产真实乱freesex| 亚洲av成人精品一区久久| 一区二区三区激情视频| 天堂动漫精品| 国产真实乱freesex| 午夜日韩欧美国产| 午夜福利18| 欧美在线一区亚洲| 一本精品99久久精品77| 成人av一区二区三区在线看| 国产一区二区三区在线臀色熟女| 久久久久国产一级毛片高清牌| 日本一二三区视频观看| 天堂av国产一区二区熟女人妻 | 亚洲国产看品久久| av超薄肉色丝袜交足视频| 精品久久久久久久久久久久久| 久久久久亚洲av毛片大全| 桃红色精品国产亚洲av| 久久精品亚洲精品国产色婷小说| 久久精品国产亚洲av香蕉五月| 欧美乱妇无乱码| 日韩大尺度精品在线看网址| 日本成人三级电影网站| 波多野结衣高清作品| 国产成人aa在线观看| 欧美日本视频| 男女做爰动态图高潮gif福利片| 国产av又大| 搡老熟女国产l中国老女人| 中文字幕人成人乱码亚洲影| 在线观看午夜福利视频| 成人一区二区视频在线观看| 日本五十路高清| 99国产精品一区二区蜜桃av| 99热这里只有精品一区 | 搡老岳熟女国产| 狂野欧美白嫩少妇大欣赏| 精品国产亚洲在线| 18美女黄网站色大片免费观看| 一本综合久久免费| 国产精品爽爽va在线观看网站| 99热这里只有是精品50| 色综合亚洲欧美另类图片| 欧美成人免费av一区二区三区| 精品人妻1区二区| 麻豆成人午夜福利视频| 一区二区三区激情视频| www.www免费av| 免费无遮挡裸体视频| 亚洲九九香蕉| 欧美乱码精品一区二区三区| 久久久久久久午夜电影| 成人欧美大片| 久久久水蜜桃国产精品网| 久久国产精品人妻蜜桃| 国产91精品成人一区二区三区| 婷婷丁香在线五月| 美女免费视频网站| 国内精品久久久久久久电影| 国产精品久久久久久亚洲av鲁大| 国产麻豆成人av免费视频| 999精品在线视频| 黄片大片在线免费观看| 亚洲成人免费电影在线观看| 国模一区二区三区四区视频 | 一区福利在线观看| 99热这里只有精品一区 | 久久精品国产综合久久久| 国产激情久久老熟女| 又黄又爽又免费观看的视频| 免费高清视频大片| 一级作爱视频免费观看| 国产在线精品亚洲第一网站| 悠悠久久av| 亚洲男人天堂网一区| 国产精华一区二区三区| 可以在线观看毛片的网站| 色在线成人网| 91国产中文字幕| 小说图片视频综合网站| 最近最新免费中文字幕在线| 欧美精品亚洲一区二区| 色精品久久人妻99蜜桃| av福利片在线观看| 99riav亚洲国产免费| 久久国产精品影院| 色精品久久人妻99蜜桃| 国产亚洲av高清不卡| 国模一区二区三区四区视频 | 欧美又色又爽又黄视频| 亚洲欧美激情综合另类| 女人高潮潮喷娇喘18禁视频| 最新在线观看一区二区三区| 在线视频色国产色| 色综合欧美亚洲国产小说| 丁香欧美五月| 亚洲男人的天堂狠狠| 色噜噜av男人的天堂激情| 色综合欧美亚洲国产小说| 精华霜和精华液先用哪个| 国产精品亚洲av一区麻豆| 亚洲精品一区av在线观看| 三级毛片av免费| 嫩草影视91久久| 无人区码免费观看不卡| 人人妻人人澡欧美一区二区| 国产69精品久久久久777片 | 老鸭窝网址在线观看| 婷婷亚洲欧美| 亚洲国产欧美一区二区综合| 欧美成人午夜精品| 久久午夜亚洲精品久久| 我的老师免费观看完整版| 欧美乱妇无乱码| 不卡一级毛片| 国产麻豆成人av免费视频| 亚洲 国产 在线| 美女 人体艺术 gogo| 国产精品影院久久| 国产69精品久久久久777片 | 一级片免费观看大全| 国产精品99久久99久久久不卡| 亚洲国产精品成人综合色| 免费无遮挡裸体视频| 欧美黑人巨大hd| 在线观看66精品国产| 日韩高清综合在线| 精品一区二区三区视频在线观看免费| 亚洲色图 男人天堂 中文字幕| 老汉色∧v一级毛片| 久久久国产成人免费| 午夜福利高清视频| 夜夜夜夜夜久久久久| 日韩成人在线观看一区二区三区| 婷婷丁香在线五月| 丰满的人妻完整版| 高潮久久久久久久久久久不卡| 久久精品影院6| 国产精品野战在线观看| 亚洲狠狠婷婷综合久久图片| 欧美性长视频在线观看| 午夜福利在线观看吧| 黑人巨大精品欧美一区二区mp4| 嫁个100分男人电影在线观看| 亚洲精品在线美女| 久99久视频精品免费| 午夜福利在线在线| 精品日产1卡2卡| 久久这里只有精品中国| 两个人看的免费小视频| 亚洲中文av在线| 91在线观看av| 99国产精品一区二区蜜桃av| 亚洲熟女毛片儿| 一本一本综合久久| 又粗又爽又猛毛片免费看| 免费在线观看成人毛片| 午夜视频精品福利| 亚洲精品久久国产高清桃花| 一级毛片高清免费大全| 香蕉av资源在线| 久久久久久亚洲精品国产蜜桃av| 悠悠久久av| 国模一区二区三区四区视频 | 色综合婷婷激情| 国产成年人精品一区二区| 欧美色欧美亚洲另类二区| 亚洲最大成人中文| 国产高清视频在线观看网站| 亚洲成a人片在线一区二区| 婷婷精品国产亚洲av| 国产精品日韩av在线免费观看| 在线播放国产精品三级| 久久久久久人人人人人| 日日干狠狠操夜夜爽| 亚洲精品av麻豆狂野| 搡老熟女国产l中国老女人| 99久久精品热视频| 久久精品国产99精品国产亚洲性色| 18禁观看日本| 成年人黄色毛片网站| 亚洲欧美精品综合一区二区三区| 我要搜黄色片| 中文字幕高清在线视频| 欧美在线黄色| 久久久久性生活片| 成人av一区二区三区在线看| 亚洲精华国产精华精| 在线十欧美十亚洲十日本专区| 成在线人永久免费视频| 日日夜夜操网爽| 亚洲国产精品999在线| 1024手机看黄色片| 亚洲va日本ⅴa欧美va伊人久久| 琪琪午夜伦伦电影理论片6080| 精品国产乱子伦一区二区三区| 亚洲,欧美精品.| 天堂影院成人在线观看| 在线观看一区二区三区| 精品日产1卡2卡| 国产精品久久久av美女十八| 国产97色在线日韩免费| 精品电影一区二区在线| a在线观看视频网站| 久久久久国产精品人妻aⅴ院| 欧美日韩亚洲综合一区二区三区_| 国产精品,欧美在线| 国模一区二区三区四区视频 | 久热爱精品视频在线9| 日日干狠狠操夜夜爽| 国产精品乱码一区二三区的特点| 一夜夜www| 日韩精品中文字幕看吧| 免费看美女性在线毛片视频| 国产成+人综合+亚洲专区| 欧美日韩乱码在线| netflix在线观看网站| 日韩欧美免费精品| 国产免费男女视频| 日韩欧美三级三区| 亚洲第一欧美日韩一区二区三区| 我的老师免费观看完整版| 麻豆国产av国片精品| 身体一侧抽搐| 日韩大码丰满熟妇| 成人高潮视频无遮挡免费网站| 一夜夜www| 亚洲一区二区三区不卡视频| 黄片小视频在线播放| 精品久久久久久久久久久久久| 国产av一区二区精品久久| 老司机福利观看| 国产一区在线观看成人免费| 久久久久国产一级毛片高清牌| 日韩成人在线观看一区二区三区| 夜夜夜夜夜久久久久| 免费看a级黄色片| 色av中文字幕| 亚洲熟妇熟女久久| www日本在线高清视频| 禁无遮挡网站| 国产野战对白在线观看| 久久午夜综合久久蜜桃| 午夜福利免费观看在线| 午夜激情av网站| 好男人在线观看高清免费视频| 国产野战对白在线观看| 精品久久久久久久久久久久久| 欧美日韩中文字幕国产精品一区二区三区| 一级作爱视频免费观看| 成人特级黄色片久久久久久久| 黄片大片在线免费观看| 国产99白浆流出| 欧美人与性动交α欧美精品济南到| 亚洲成人久久性| 欧美在线一区亚洲| 欧美乱码精品一区二区三区| 日韩欧美免费精品| 亚洲午夜理论影院| 天堂动漫精品| 啦啦啦观看免费观看视频高清| 欧美性猛交黑人性爽| 国产精品野战在线观看| 一二三四社区在线视频社区8| 午夜精品一区二区三区免费看| 1024香蕉在线观看| 国产精品久久电影中文字幕| 国产av一区二区精品久久| 国产人伦9x9x在线观看| 美女黄网站色视频| 免费在线观看日本一区| 久久中文看片网| 级片在线观看| 亚洲男人天堂网一区| 两个人看的免费小视频| 一进一出好大好爽视频| 亚洲国产精品久久男人天堂| 婷婷六月久久综合丁香| 亚洲人与动物交配视频| 妹子高潮喷水视频| a在线观看视频网站| 黄色成人免费大全| 色播亚洲综合网| 白带黄色成豆腐渣| 精品国产乱码久久久久久男人| 国产av麻豆久久久久久久| 久久精品影院6| 真人做人爱边吃奶动态| 琪琪午夜伦伦电影理论片6080| 精品久久久久久久久久免费视频| 美女黄网站色视频| 级片在线观看| 日本精品一区二区三区蜜桃| 99精品在免费线老司机午夜| 亚洲狠狠婷婷综合久久图片| 亚洲va日本ⅴa欧美va伊人久久| 一个人观看的视频www高清免费观看 | 桃红色精品国产亚洲av| 日韩精品中文字幕看吧| 免费看美女性在线毛片视频| 中文资源天堂在线| 舔av片在线| 不卡av一区二区三区| 久久精品成人免费网站| 91字幕亚洲| 校园春色视频在线观看| 美女黄网站色视频| 久久久久久久久中文| 18禁美女被吸乳视频| 精品不卡国产一区二区三区| 一本久久中文字幕| 亚洲一区二区三区色噜噜| 一进一出抽搐动态| av天堂在线播放| 精品欧美一区二区三区在线| 久久婷婷人人爽人人干人人爱| 91大片在线观看| 亚洲精品国产精品久久久不卡| 国产午夜精品论理片| 亚洲aⅴ乱码一区二区在线播放 | 成年人黄色毛片网站| 99re在线观看精品视频| 波多野结衣巨乳人妻| 国产成人影院久久av| 国产成人系列免费观看| 国产精品野战在线观看| www.www免费av| 丁香欧美五月| 一级毛片高清免费大全| 十八禁人妻一区二区| 搡老岳熟女国产| 一级毛片高清免费大全| 嫁个100分男人电影在线观看| 美女免费视频网站| 一区二区三区国产精品乱码| 男人的好看免费观看在线视频 | 精品一区二区三区av网在线观看| 69av精品久久久久久| 精品人妻1区二区| 高潮久久久久久久久久久不卡| 久久亚洲真实| 色在线成人网| 丁香六月欧美| 男插女下体视频免费在线播放| 99re在线观看精品视频| 99久久99久久久精品蜜桃| 毛片女人毛片| 久久精品aⅴ一区二区三区四区| 欧美日本视频| 午夜精品久久久久久毛片777| 两个人免费观看高清视频| 久久精品亚洲精品国产色婷小说| 欧美日韩一级在线毛片| 宅男免费午夜| 成人国产综合亚洲| e午夜精品久久久久久久| 九色成人免费人妻av| 国产视频一区二区在线看| 特大巨黑吊av在线直播| a级毛片a级免费在线| 国产一区二区三区视频了| 亚洲男人的天堂狠狠|